Spyre Therapeutics Inc. (SYRE) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.97x
Spyre Therapeutics Inc. (SYRE) has a Cash Flow-to-Debt Ratio of -0.97x as of June 2026, meaning its operating cash flow of $-69.88 Million could theoretically repay -1% of its total liabilities ($71.86 Million) in one year. See Spyre Therapeutics Inc. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.97x
Operating CF / Total Liabilities
Operating Cash Flow
$-69.88 Million
USD
Total Liabilities
$71.86 Million
USD
Data as of
Jun 2026
Most recent filing
Spyre Therapeutics Inc. Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Spyre Therapeutics Inc. across 12 annual periods. For the full cash flow conversion analysis, see Spyre Therapeutics Inc. (SYRE) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Spyre Therapeutics Inc. (2014–2025)
Year-by-year debt coverage analysis for Spyre Therapeutics Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.71x | $-169.25 Million | $62.55 Million | ▼ -55.9% |
| 2024 | -1.74x | $-157.41 Million | $90.68 Million | ▼ -174.2% |
| 2023 | -0.63x | $-99.91 Million | $157.84 Million | ▲ +83.5% |
| 2022 | -3.85x | $-80.14 Million | $20.84 Million | ▼ -86.0% |
| 2021 | -2.07x | $-53.72 Million | $25.98 Million | ▲ +40.6% |
| 2020 | -3.48x | $-75.78 Million | $21.79 Million | ▼ -22.3% |
| 2019 | -2.84x | $-65.69 Million | $23.10 Million | ▲ +8.9% |
| 2018 | -3.12x | $-32.19 Million | $10.31 Million | ▲ +27.2% |
| 2017 | -4.29x | $-24.61 Million | $5.74 Million | ▲ +6.7% |
| 2016 | -4.60x | $-18.84 Million | $4.10 Million | ▼ -6.8% |
| 2015 | -4.31x | $-10.98 Million | $2.55 Million | ▲ +37.9% |
| 2014 | -6.93x | $-7.33 Million | $1.06 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.